Strategic Partnerships IMI has recent high-profile partnerships with Grifols and Kiro Grifols focused on automated pharmacy compounding devices, signaling opportunities to cross-sell tamper-evident delivery solutions and secure drug delivery technologies to large pharma and specialty pharmacy ecosystems.

Market Expansion Expansion into the home health market via a partnership with Integrated Medical Systems indicates growing channels beyond traditional hospital and clinical settings, suggesting sales potential for portable secure delivery devices and compatible adapters for home use.

Regulatory Strength ISO 13485:2003 and CMDCAS & Medical Devices Directive 93/42/EEC certifications underscore compliance maturity, enabling easier penetration into regulated markets and conversations with customers prioritizing quality management and international conformity.

Technology Leadership IMI’s focus on tamper evident technologies for IV syringes and delivery systems, combined with RFID/DoseID involvement, positions the company to offer integrated, traceable medication safety solutions to hospitals, clinics, and pharmaceutical manufacturers.

Financial & Scale With a revenue range of 10M-25M and a leaner employee base relative to peers, there is potential for scalable partnerships, OEM opportunities, and selective add-ons or module sales to expand product adoption without a heavy gross margin drag.